CMMB FY 2024 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$53,251

Operating Income

-$15M

Net Income

-$14M

EPS (Diluted)

$-3.12

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$17M

Total Liabilities

$3M

Stockholders' Equity

$14M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$53,251	-$66,827	+20.3%
Operating Income	-$15M	-$25M	+42.1%
Net Income	-$14M	-$24M	+42.4%